Cardiovascular pharmacotherapy in 2025

Despite recent advances in cardiovascular pharmacotherapy, prevention and treatment of many cardiovascular diseases remain limited with a clear need for more effective and safer pharmacological strategies. Here, we summarize the most relevant advances in cardiovascular pharmacotherapy in 2025, including the approval of four new drugs (aficamten, etripamil, lerodalcibep, and plozasiran), the label expansions for five already approved drugs, and the results of major randomized clinical trials with already approved drugs, including those that met the prespecified primary endpoints (positive trials) representing new pharmacological options for cardiovascular diseases, those with neutral or negative results, which did not confirm the primary endpoints and the withdrawal from the US market of Andexanet-alfa for safety concerns. Finally, we present the most promising experimental cardiovascular drugs currently being investigated in ongoing Phase 2 and 3 clinical trials.

Descrição

A correction has been published: European Heart Journal - Cardiovascular Pharmacotherapy, Volume 12, Issue 3, May 2026, Page 231, https://doi.org/10.1093/ehjcvp/pvag028
Supplementary material is available at European Heart Journal—Cardiovascular Pharmacotherapy online.

Palavras-chave

Cardiovascular drugs Cardiovascular pharmacotherapy Pharmacological strategies

URI

http://hdl.handle.net/10400.8/16831

Citação

Juan Tamargo, Stefan Agewall, Giuseppe Ambrosio, Claudio Borghi, Elisabetta Cerbai, Gheorghe A Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Roland Klingenberg, Joao Morais, William Parker, Bianca Rocca, Patrick Sulzgruber, Anne Grete Semb, Samuel Sossalla, Juan Carlos Kaski, Dobromir Dobrev, Cardiovascular pharmacotherapy in 2025, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 12, Issue 3, May 2026, Pages 147–166, https://doi.org/10.1093/ehjcvp/pvag016

Editora

Oxford University Press

DOI

10.1093/ehjcvp/pvag016

Coleções

ciTechCare - Artigos
ESSLei - Artigos em revistas internacionais

Licença CC

cclicense-by

Métricas Alternativas

Ver registo completo